Binance Labs invests in BIO Protocol to revolutionize decentralized science

Source Cryptopolitan

Binance Labs, the crypto exchange’s venture capital arm, has invested in decentralized science (DeSci) by backing the BIO Protocol. This accelerator is designed to help early-stage scientific research startups access decentralized funding opportunities.

BIO Protocol expands its BioDAO network

BIO Protocol promotes a network of Biotech Decentralized Autonomous Organizations (BioDAOs), which form communities to fund, develop, and co-own innovative pharmaceuticals and therapies. According to Binance Labs, BioDAOs solve gaps in traditional funding for rare diseases, longevity research, and emergent health concerns.

The details of the investment’s exact amount were not disclosed, but it will enable BIO Protocol to grow its network by providing seed funding for new projects and strengthening community and tokenomics support. Binance Labs’ Investment Director Andy Chang commented:

“BIO Protocol represents a significant step forward in DeSci by merging biotechnology and DeFi. At Binance Labs, we are dedicated to unlocking groundbreaking advancements that drive long-term, real-world impact by supporting projects building meaningful technology.”

~Andy Chang

Binance Labs has more than 200 projects in its portfolio, most of which contribute to the development of decentralized finance. However, some involve gaming, artificial intelligence, and other sectors. For instance, Binance Labs supports Pluto Studio, which established the popular tap-to-earn Telegram mini-app Catizen.

Binance Labs and BIO Protocol to support IP-driven DAOs

BIO Protocol’s network of eight BioDAOs had a market capitalization of $200 million in November 2023. As co-founder of the Molecule platform, BIO Protocol’s Paul Kohlhaas introduced intellectual property non-fungible tokens (IP-NFTs). The protocol supports the sale of IP-NFTs.

One of BIO Protocol’s cornerstone projects, longevity-focused VitaDAO, was founded in 2021. In February 2023, it obtained $4.1 million in funding from pharmaceutical manufacturer Pfizer and supported the launch of Matrix Biosciences in October.

According to Binance Labs, the protocol’s next batch will feature projects to find a cure for Long COVID and rare diseases and build quantum microscopes to examine quantum biological processes.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Forecast: XAU/USD gains momentum to near $3,650, eyes on US CPI releaseThe Gold price (XAU/USD) gains momentum to near $3,645 during the early Asian session on Thursday.
Author  FXStreet
Sep 11, Thu
The Gold price (XAU/USD) gains momentum to near $3,645 during the early Asian session on Thursday.
placeholder
Silver Price Forecast: XAG/USD plummets below $48 on US-China trade deal optimismSilver price (XAG/USD) trades 1.5% lower, slightly below $48.00 during the late Asian trading session on Monday.
Author  FXStreet
Oct 27, Mon
Silver price (XAG/USD) trades 1.5% lower, slightly below $48.00 during the late Asian trading session on Monday.
placeholder
Fed’s October Rate Cut: Easing Cycle Continues, Gold Likely to Keep RisingLooking ahead, the Federal Reserve's interest rate meeting on 29 October will be a pivotal event shaping gold price trends.
Author  TradingKey
Oct 27, Mon
Looking ahead, the Federal Reserve's interest rate meeting on 29 October will be a pivotal event shaping gold price trends.
placeholder
4 US Economic Events with Crypto Implications This WeekThis week will be action-packed, with multiple US economic events scheduled that are poised to influence traders’ and investors’ portfolios.
Author  Beincrypto
Oct 27, Mon
This week will be action-packed, with multiple US economic events scheduled that are poised to influence traders’ and investors’ portfolios.
placeholder
Microsoft Q1 Earnings Preview: AI-Powered Cloud Growth Fuels Wall Street’s “Zero Sell” ConsensusMicrosoft has beaten EPS estimates in nine of the past ten quarters. If Q3 delivers strong results, it would mark the 10th consecutive beat.
Author  TradingKey
15 hours ago
Microsoft has beaten EPS estimates in nine of the past ten quarters. If Q3 delivers strong results, it would mark the 10th consecutive beat.
goTop
quote